Feng, Hwa-Ping <br/><br/>
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.  [electronic resource] 

 -  The Journal of antimicrobial chemotherapy  03 2019 
 - 710-717 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2091 
<br/><br/><label>Standard No.: </label>10.1093/jac/dky465  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Amides<br/>Antiretroviral Therapy, Highly Active<br/>Antiviral Agents--administration & dosage<br/>Benzofurans--administration & dosage<br/>Carbamates<br/>Chromatography, Liquid<br/>Coinfection--drug therapy<br/>Cyclopropanes<br/>Drug Interactions<br/>Drug Monitoring<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--drug therapy<br/>HIV Integrase Inhibitors--administration & dosage<br/>Hepatitis C--drug therapy<br/>Heterocyclic Compounds, 3-Ring--administration & dosage<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Mass Spectrometry<br/>Middle Aged<br/>Oxazines<br/>Piperazines<br/>Pyridones<br/>Quinoxalines--administration & dosage<br/>Raltegravir Potassium--administration & dosage<br/>Sulfonamides<br/>Treatment Outcome<br/>Young Adult